UPDATE: Wedbush Downgrades MAP Pharma (MAPP) to Neutral, Notes Other Potential M&A Targets
Tweet Send to a FriendGet Alerts MAPP Hot Sheet
Price: $24.98 --0%
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 21
Trade MAPP Now!
(Updated - March 1, 2013 1:58 PM EST)
Wedbush downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Outperform to Neutral with a price target of $25.
"We are downgrading MAPP to NEUTRAL from OUTPERFORM due to the increased likelihood of its acquisition by Allergan (NYSE: AGN) and reiterating our $25 fair value," said analyst Liana Moussatos.
Moussatos believes Allergan's acquisition of MAPP may suggest that other companies with migraine products will become acquisition targets for pharmaceutical companies such as GlaxoSmithKline (NYSE: GSK) and Merck (NYSE: MRK).
Companies mentioned include NuPathe, Inc. (Nasdaq: PATH), POZEN Inc. (Nasdaq: POZN) and Zogenix (Nasdaq: ZGNX).
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For more ratings news on MAP Pharmaceuticals click here.
Shares of MAP Pharmaceuticals closed at $25.00 yesterday, with a 52 week range of $11.11-$25.03.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Wedbush downgraded MAP Pharmaceuticals (NASDAQ: MAPP) from Outperform to Neutral with a price target of $25.
"We are downgrading MAPP to NEUTRAL from OUTPERFORM due to the increased likelihood of its acquisition by Allergan (NYSE: AGN) and reiterating our $25 fair value," said analyst Liana Moussatos.
Moussatos believes Allergan's acquisition of MAPP may suggest that other companies with migraine products will become acquisition targets for pharmaceutical companies such as GlaxoSmithKline (NYSE: GSK) and Merck (NYSE: MRK).
Companies mentioned include NuPathe, Inc. (Nasdaq: PATH), POZEN Inc. (Nasdaq: POZN) and Zogenix (Nasdaq: ZGNX).
For an analyst ratings summary and ratings history on MAP Pharmaceuticals click here. For more ratings news on MAP Pharmaceuticals click here.
Shares of MAP Pharmaceuticals closed at $25.00 yesterday, with a 52 week range of $11.11-$25.03.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Bernstein Cuts BlackBerry (BBRY) to Underperform; Notes Weak BB10 Traction
- Goldman Sachs Upgrades Tanger Factory Outlet Centers (SKT) to Neutral
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
Create E-mail Alert Related Categories
Analyst Comments, Downgrades, Mergers and Acquisitions
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
